PLX
Protalix BioTherapeutics, Inc.
2.30
400 x undefined
15300 x undefined
bid
ask
-
0.03
1.29%
7850 @ 04:00 PM
2.33 +0.03 (1.36%)
| Ytd | 27.78% | |
| 1y | 53.33% |
2.26
day range
2.33
1.36
52 week range
3.19
| Open | 2.31 | Prev Close | 2.33 | Low | 2.26 | High | 2.33 | Mkt Cap | 185.31M |
| Vol | 436.23K | Avg Vol | 735.79K | EPS | 0.19 | P/E | 12.11 | Forward P/E | 2.79 |
| Beta | 0.67 | Short Ratio | 22.71 | Inst. Own | 5.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.08 | 200-d Avg | 2.20 | 1yr Est | 14.00 |
| Income Statement | |||
| Total Revenue | 33.75M | ||
| Revenues (USD) | 33.75M | ||
| Cost of Revenue | 4.13M | ||
| Gross Profit | 29.62M | ||
| Operating Expenses | 8.48M | ||
| Research and Development Expense | 5.43M | ||
| Selling, General and Administrative Expense | 3.05M | ||
| Operating Income | 21.15M | ||
| Interest Expense | 193.00K | ||
| Income Tax Expense | 2.82M | ||
| Net Income | 18.32M | ||
| Net Income Common Stock | 18.32M | ||
| Net Income Common Stock (USD) | 18.32M | ||
| Consolidated Income | 18.32M | ||
| Earnings per Basic Share | 0.23 | ||
| Earnings per Basic Share (USD) | 0.23 | ||
| Earnings per Diluted Share | 0.22 | ||
| Earning Before Interest & Taxes (EBIT) | 21.33M | ||
| Earning Before Interest & Taxes (USD) | 21.33M | ||
| Weighted Average Shares | 79.85M | ||
| Weighted Average Shares Diluted | 83.05M | ||
| Balance Sheet | |||
| Cash and Equivalents | 41.71M | ||
| Cash and Equivalents (USD) | 41.71M | ||
| Investments | 10.08M | ||
| Investments Current | 10.08M | ||
| Trade and Non-Trade Receivables | 2.94M | ||
| Current Assets | 86.36M | ||
| Property, Plant & Equipment Net | 12.95M | ||
| Total Assets | 102.34M | ||
| Debt Current | 1.43M | ||
| Total Debt | 8.48M | ||
| Current Liabilities | 27.39M | ||
| Debt Non-Current | 7.05M | ||
| Total Liabilities | 35.11M | ||
| Shareholders Equity | 67.23M | ||
| Shareholders Equity (USD) | 67.23M | ||
| Assets Non-Current | 15.98M | ||
| Total Debt (USD) | 8.48M | ||
| Inventory | 30.47M | ||
| Liabilities Non-Current | 7.72M | ||
| Trade and Non-Trade Payables | 25.96M | ||
| Tax Assets | 2.44M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 404.00K | ||
| Net Cash Flow from Financing | 150.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 26.32M | ||
| Capital Expenditure | -761.00K | ||
| Issuance (Purchase) of Equity Shares | 150.00K | ||
| Net Cash Flow from Investing | 4.22M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 5.00M | ||
| Net Cash Flow from Operations | 22.03M | ||
| Effect of Exchange Rate Changes on Cash | -77.00K | ||
| Share Based Compensation | 532.00K | ||